Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00949650




Registration number
NCT00949650
Ethics application status
Date submitted
29/07/2009
Date registered
29/07/2009
Date last updated
9/03/2018

Titles & IDs
Public title
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Scientific title
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Secondary ID [1] 0 0
2008-005615-18
Secondary ID [2] 0 0
1200.32
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Non-Small-Cell Lung 0 0
Adenocarcinoma 0 0
Carcinoma, Non-Small-Cell Lung 0 0
Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pemetrexed
Treatment: Drugs - BIBW 2992
Treatment: Drugs - Cisplatin
Treatment: Drugs - Pemetrexed
Treatment: Drugs - BIBW 2992
Treatment: Drugs - Cisplatin

Experimental: BIBW 2992 - BIBW 2992 tablet once daily until progression

Active Comparator: Cisplatin/Pemetrexed - Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles

Experimental: BIBW 2992 - BIBW 2992 tablet once daily until progression

Active Comparator: Cisplatin/Pemetrexed - Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles


Treatment: Drugs: Pemetrexed
Pemetrexed IV given once every 3 weeks for up to 6 cycles

Treatment: Drugs: BIBW 2992
BIBW 2992 once daily until progression

Treatment: Drugs: Cisplatin
Cisplatin IV given once every 3 weeks for up to 6 cycles

Treatment: Drugs: Pemetrexed
Pemetrexed IV given once every 3 weeks for up to 6 cycles

Treatment: Drugs: BIBW 2992
BIBW 2992 once daily until progression

Treatment: Drugs: Cisplatin
Cisplatin IV given once every 3 weeks for up to 6 cycles

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) Time - PFS was defined as time from randomisation to disease progression or death whichever occured first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates.
Timepoint [1] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Primary outcome [2] 0 0
Progression-Free Survival (PFS) Time - PFS was defined as time from randomisation to disease progression or death whichever occured first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates.
Timepoint [2] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [1] 0 0
Percentage of Patients With Objective Response (OR) - OR was defined as Complete Response (CR) or Partial Response (PR). Assessed by central independent review according to RECIST 1.1.
Timepoint [1] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [2] 0 0
Percentage of Participants With Disease Control (DC) - DC was defined as a patient with OR or Stable Disease (SD). Assessed by central independent review according to the RECIST 1.1.
Timepoint [2] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [3] 0 0
Overall Survival (OS) Time - OS was defined as time from randomisation to death.
Timepoint [3] 0 0
From randomisation to cut-off date (17MAR2017).
Secondary outcome [4] 0 0
Tumour Shrinkage - Tumour shrinkage was calculated as the minimum Sum of Diameters (SoD) of target lesions from all post-baseline tumour assessments, as read by the central independent review. The mean of these minimum values were presented after adjusting for baseline SoD, EGFR mutation group and race.
Timepoint [4] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [5] 0 0
Change From Baseline in Body Weight - Because the PFS was longer for patients in the Afatinib arm than for patients in the chemotherapy arm, the period of data collection for ECOG status and body weight continued for a longer time in the Afatinib arm.
Timepoint [5] 0 0
Baseline and throughout the trial until progression (every 3 weeks), up to 28 months.
Secondary outcome [6] 0 0
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) - ECOG PS measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction.
Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work.
Ambulatory (>50 percent of waking hours), capable of all self-care, unable to carry out any work activities.
Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours.
Completely disabled, cannot carry on any self-care, totally confined to bed or chair.
Dead.
Timepoint [6] 0 0
Throughout the trial until progression (every 3 weeks), up to 28 months.
Secondary outcome [7] 0 0
Health Related Quality of Life (HRQOL): Time to Deterioration in Coughing - HRQOL was measured by European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire C30 (QLQ-C30) and its lung cancer specific module LC13 (QLQ-LC13). Analysis for cough is based on QLQ-LC13 question 1. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.
Timepoint [7] 0 0
Throughout the trial until progression (every 3 weeks).
Secondary outcome [8] 0 0
HRQOL: Time to Deterioration in Dyspnoea - HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for dyspnoea is based on composite of QLQ-LC13 questions 3-5. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.
Timepoint [8] 0 0
Throughout the trial until progression (every 3 weeks).
Secondary outcome [9] 0 0
HRQOL: Time to Deterioration in Pain - HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for pain is based on composite of QLQ-C30 questions 9 and 19. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.
Timepoint [9] 0 0
Throughout the trial until progression (every 3 weeks).
Secondary outcome [10] 0 0
Trough Plasma Concentrations of Afatinib at Day 22 - Trough plasma concentrations of Afatinib at Day 22 (course 2, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.
Timepoint [10] 0 0
Day 22.
Secondary outcome [11] 0 0
Trough Plasma Concentrations of Afatinib at Day 29 - Trough plasma concentrations of Afatinib at day 29 (course 2, visit 2) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.
Timepoint [11] 0 0
Day 29.
Secondary outcome [12] 0 0
Trough Plasma Concentrations of Afatinib at Day 43 - Trough plasma concentrations of Afatinib at Day 43 (course 3, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.
Timepoint [12] 0 0
Day 43.
Secondary outcome [13] 0 0
Percentage of Patients With Objective Response (OR) - OR was defined as Complete Response (CR) or Partial Response (PR). Assessed by central independent review according to RECIST 1.1.
Timepoint [13] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [14] 0 0
Percentage of Participants With Disease Control (DC) - DC was defined as a patient with OR or Stable Disease (SD). Assessed by central independent review according to the RECIST 1.1.
Timepoint [14] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [15] 0 0
Overall Survival (OS) Time - OS was defined as time from randomisation to death.
Timepoint [15] 0 0
From randomisation to cut-off date (17MAR2017).
Secondary outcome [16] 0 0
Tumour Shrinkage - Tumour shrinkage was calculated as the minimum Sum of Diameters (SoD) of target lesions from all post-baseline tumour assessments, as read by the central independent review. The mean of these minimum values were presented after adjusting for baseline SoD, EGFR mutation group and race.
Timepoint [16] 0 0
Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression
Secondary outcome [17] 0 0
Change From Baseline in Body Weight - Because the PFS was longer for patients in the Afatinib arm than for patients in the chemotherapy arm, the period of data collection for ECOG status and body weight continued for a longer time in the Afatinib arm.
Timepoint [17] 0 0
Baseline and throughout the trial until progression (every 3 weeks), up to 28 months.
Secondary outcome [18] 0 0
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) - ECOG PS measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction.
Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work.
Ambulatory (>50 percent of waking hours), capable of all self-care, unable to carry out any work activities.
Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours.
Completely disabled, cannot carry on any self-care, totally confined to bed or chair.
Dead.
Timepoint [18] 0 0
Throughout the trial until progression (every 3 weeks), up to 28 months.
Secondary outcome [19] 0 0
Health Related Quality of Life (HRQOL): Time to Deterioration in Coughing - HRQOL was measured by European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire C30 (QLQ-C30) and its lung cancer specific module LC13 (QLQ-LC13). Analysis for cough is based on QLQ-LC13 question 1. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.
Timepoint [19] 0 0
Throughout the trial until progression (every 3 weeks).
Secondary outcome [20] 0 0
HRQOL: Time to Deterioration in Dyspnoea - HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for dyspnoea is based on composite of QLQ-LC13 questions 3-5. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.
Timepoint [20] 0 0
Throughout the trial until progression (every 3 weeks).
Secondary outcome [21] 0 0
HRQOL: Time to Deterioration in Pain - HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for pain is based on composite of QLQ-C30 questions 9 and 19. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.
Timepoint [21] 0 0
Throughout the trial until progression (every 3 weeks).
Secondary outcome [22] 0 0
Trough Plasma Concentrations of Afatinib at Day 22 - Trough plasma concentrations of Afatinib at Day 22 (course 2, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.
Timepoint [22] 0 0
Day 22.
Secondary outcome [23] 0 0
Trough Plasma Concentrations of Afatinib at Day 29 - Trough plasma concentrations of Afatinib at day 29 (course 2, visit 2) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.
Timepoint [23] 0 0
Day 29.
Secondary outcome [24] 0 0
Trough Plasma Concentrations of Afatinib at Day 43 - Trough plasma concentrations of Afatinib at Day 43 (course 3, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.
Timepoint [24] 0 0
Day 43.

Eligibility
Key inclusion criteria
Inclusion criteria:

- Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural
effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients
with mixed histology are eligible if adenocarcinoma is the predominant histology.

- Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of
tumour biopsy material.

- Measurable disease according to RECIST 1.1.

- Eastern Cooperative Oncology Group score of 0 or 1.

- Age >/= 18 years.

- Life expectancy of at least three months.

- Written informed consent that is consistent with International Conference on
Harmonisation-Good Clinical Practice guidelines.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant
chemotherapy is permitted if at least 12 months has elapsed between the end of
chemotherapy and randomisation.

- Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or
antibodies.

- Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation.

- Active brain metastases

- Any other current malignancy or malignancy diagnosed within the past five years

- Known pre-existing interstitial lung disease.

- Significant or recent acute gastrointestinal disorders with diarrhoea as a major
symptom.

- History or presence of clinically relevant cardiovascular abnormalities.

- Any other concomitant serious illness or organ system dysfunction.

- Adequate absolute neutrophil count and platelet count

- Adequate liver and kidney function

- Active hepatitis B infection, active hepatitis C infection or known HIV carrier.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Lifehouse - Camperdown
Recruitment hospital [2] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 0 0
Calvary Mater Newcastle Hospital - Waratah
Recruitment hospital [4] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [5] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [6] 0 0
The Burnside War Memorial Hospital - Toorak Gardens
Recruitment hospital [7] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [8] 0 0
St. Vincents Hospital (MEL) - Fitzroy
Recruitment hospital [9] 0 0
Mount Medical Centre - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
2298 - Waratah
Recruitment postcode(s) [4] 0 0
4032 - Chermside
Recruitment postcode(s) [5] 0 0
5042 - Bedford Park
Recruitment postcode(s) [6] 0 0
5065 - Toorak Gardens
Recruitment postcode(s) [7] 0 0
3128 - Box Hill
Recruitment postcode(s) [8] 0 0
3065 - Fitzroy
Recruitment postcode(s) [9] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Pennsylvania
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
Argentina
State/province [8] 0 0
Bahía Blanca
Country [9] 0 0
Argentina
State/province [9] 0 0
Capital Federal
Country [10] 0 0
Argentina
State/province [10] 0 0
Rosario
Country [11] 0 0
Austria
State/province [11] 0 0
Linz
Country [12] 0 0
Austria
State/province [12] 0 0
Wels
Country [13] 0 0
Austria
State/province [13] 0 0
Wien
Country [14] 0 0
Belgium
State/province [14] 0 0
Bruxelles
Country [15] 0 0
Belgium
State/province [15] 0 0
Gent
Country [16] 0 0
Belgium
State/province [16] 0 0
Jette
Country [17] 0 0
Belgium
State/province [17] 0 0
Leuven
Country [18] 0 0
Belgium
State/province [18] 0 0
Liège
Country [19] 0 0
Brazil
State/province [19] 0 0
Belo Horizonte
Country [20] 0 0
Brazil
State/province [20] 0 0
Cachoeiro de Itapemirim
Country [21] 0 0
Brazil
State/province [21] 0 0
Curitiba
Country [22] 0 0
Brazil
State/province [22] 0 0
Porto Alegre
Country [23] 0 0
Brazil
State/province [23] 0 0
Sao Paulo
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
Migration Data
Country [26] 0 0
Chile
State/province [26] 0 0
Los Condes
Country [27] 0 0
Chile
State/province [27] 0 0
Reñaca
Country [28] 0 0
Chile
State/province [28] 0 0
Temuco
Country [29] 0 0
France
State/province [29] 0 0
Angers
Country [30] 0 0
France
State/province [30] 0 0
Caen Cedex 5
Country [31] 0 0
France
State/province [31] 0 0
La Tronche
Country [32] 0 0
France
State/province [32] 0 0
Lyon Cedex 4
Country [33] 0 0
France
State/province [33] 0 0
Paris Cedex 05
Country [34] 0 0
France
State/province [34] 0 0
Saint Herblain
Country [35] 0 0
France
State/province [35] 0 0
Saint Pierre - La Réunion
Country [36] 0 0
France
State/province [36] 0 0
Toulon
Country [37] 0 0
France
State/province [37] 0 0
Villefranche Sur Saône
Country [38] 0 0
Germany
State/province [38] 0 0
Berlin
Country [39] 0 0
Germany
State/province [39] 0 0
Essen
Country [40] 0 0
Germany
State/province [40] 0 0
Hannover
Country [41] 0 0
Germany
State/province [41] 0 0
Hemer
Country [42] 0 0
Germany
State/province [42] 0 0
Mainz
Country [43] 0 0
Germany
State/province [43] 0 0
Münster
Country [44] 0 0
Germany
State/province [44] 0 0
Oldenburg
Country [45] 0 0
Germany
State/province [45] 0 0
Taipei
Country [46] 0 0
Hong Kong
State/province [46] 0 0
Hong Kong
Country [47] 0 0
Hong Kong
State/province [47] 0 0
Shatin
Country [48] 0 0
Hungary
State/province [48] 0 0
Szekesfehervar
Country [49] 0 0
Hungary
State/province [49] 0 0
Szombathely
Country [50] 0 0
Hungary
State/province [50] 0 0
Zalaegerszeg
Country [51] 0 0
Ireland
State/province [51] 0 0
Dublin 8
Country [52] 0 0
Italy
State/province [52] 0 0
Arezzo
Country [53] 0 0
Italy
State/province [53] 0 0
Prato
Country [54] 0 0
Italy
State/province [54] 0 0
Roma
Country [55] 0 0
Italy
State/province [55] 0 0
Sant'Andrea Delle Fratte (PG)
Country [56] 0 0
Japan
State/province [56] 0 0
Aichi, Nagoya
Country [57] 0 0
Japan
State/province [57] 0 0
Chiba, Kashiwa
Country [58] 0 0
Japan
State/province [58] 0 0
Ehime, Matsuyama
Country [59] 0 0
Japan
State/province [59] 0 0
Fukuoka, Fukuoka
Country [60] 0 0
Japan
State/province [60] 0 0
Hokkaido, Sapporo
Country [61] 0 0
Japan
State/province [61] 0 0
Hyogo, Kobe
Country [62] 0 0
Japan
State/province [62] 0 0
Ishikawa, Kanazawa
Country [63] 0 0
Japan
State/province [63] 0 0
Kanagawa, Yokohama
Country [64] 0 0
Japan
State/province [64] 0 0
Niigata, Niigata
Country [65] 0 0
Japan
State/province [65] 0 0
Okayama, Kurashiki
Country [66] 0 0
Japan
State/province [66] 0 0
Okayama, Okayama
Country [67] 0 0
Japan
State/province [67] 0 0
Osaka, Osaka-Sayama
Country [68] 0 0
Japan
State/province [68] 0 0
Osaka, Osaka
Country [69] 0 0
Japan
State/province [69] 0 0
Sakai, Osaka
Country [70] 0 0
Japan
State/province [70] 0 0
Shizuoka, Sunto-gun
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Cheongju
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Hwasun
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Seongnam
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Seoul
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Ulsan
Country [76] 0 0
Malaysia
State/province [76] 0 0
Palau Pinang
Country [77] 0 0
Malaysia
State/province [77] 0 0
Wilayah Persekutuan
Country [78] 0 0
Peru
State/province [78] 0 0
La Victoria
Country [79] 0 0
Peru
State/province [79] 0 0
San Isidro
Country [80] 0 0
Peru
State/province [80] 0 0
Surquillo
Country [81] 0 0
Philippines
State/province [81] 0 0
Cebu City
Country [82] 0 0
Philippines
State/province [82] 0 0
Makati City
Country [83] 0 0
Philippines
State/province [83] 0 0
Quezon
Country [84] 0 0
Romania
State/province [84] 0 0
Cluj Napoca
Country [85] 0 0
Romania
State/province [85] 0 0
Craiova
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Kazan
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Moscow
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Obninsk
Country [89] 0 0
Russian Federation
State/province [89] 0 0
St. Petersburg
Country [90] 0 0
Taiwan
State/province [90] 0 0
Kaohsiung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taichung
Country [92] 0 0
Taiwan
State/province [92] 0 0
Tainan
Country [93] 0 0
Taiwan
State/province [93] 0 0
Taipei
Country [94] 0 0
Taiwan
State/province [94] 0 0
Taoyuan
Country [95] 0 0
Thailand
State/province [95] 0 0
Bangkok
Country [96] 0 0
Thailand
State/province [96] 0 0
Chiang Mai
Country [97] 0 0
Thailand
State/province [97] 0 0
Khonkaen
Country [98] 0 0
Thailand
State/province [98] 0 0
Songkla
Country [99] 0 0
Ukraine
State/province [99] 0 0
Dnipropetrovsk
Country [100] 0 0
Ukraine
State/province [100] 0 0
Donetsk
Country [101] 0 0
Ukraine
State/province [101] 0 0
Kharkiv
Country [102] 0 0
Ukraine
State/province [102] 0 0
Lviv
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Exeter
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Guildford
Country [105] 0 0
United Kingdom
State/province [105] 0 0
London
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Maidstone
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Scunthorpe
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Sutton
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomised, open label phase III trial will be performed in patients with adenocarcinoma
of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation.
The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A,
with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of
patients.
Trial website
https://clinicaltrials.gov/show/NCT00949650
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications